The aim of our study is the optimization and evaluation of smart polymer-based systems for graft-targeted immunotherapy, as they could help minimize overall load/exposure (dosing, timing and frequency) of systemic immunosuppressionThis therapeutic platform incorporates injectable, monolithic, self-healing, biocompatible drug eluting hydrogels capable of not only sustained, stable release but also "on- demand" pulsed/burst release upon graft immune responses.Technical Risk(s): Do not anticipate issues at this time.